Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on NOVO NORDISK A/S
04:58p DONG Energy - One of the largest power stations in Denmark can phase out coal
06/26 NOVO NORDISK A/S : - Share repurchase programme
06/24 NOVO NORDISK A/S : Announces Headline Results Of Semaglutide
06/24 NOVO NORDISK A/S : Novos Saxenda label to include cardio data
06/24 NOVO NORDISK A/S : reports up to 13.8% weight loss in people with obesity receiv..
06/23 NOVO NORDISK A/S : rapporterer op til 13,8% vægttab hos svært overvægtige mennes..
06/23 NOVO NORDISK A/S : reports up to 13.8% weight loss in people with obesity receiv..
06/23 NOVO NORDISK A/S : reports up to 13.8% weight loss in people with obesity receiv..
06/23 NOVO NORDISK A/S : CHMP endorses EU label update of Saxenda based on the LEADER ..
06/23 NOVO NORDISK A/S : CHMP adopts positive opinion for EU label update of Victoza® ..
06/22 NOVO NORDISK A/S : Tresiba® demonstrated no increased risk of major cardiovascul..
06/22 NOVO NORDISK A/S : New LEADER Analysis Shows Victoza Reduces Cardiovascular Risk..
06/22 NOVO NORDISK A/S : CHMP endorses EU label update of Saxenda® based on the LEADER..
06/22 NOVO NORDISK A/S : FDA panel supports cardiovascular indication for Novos diabet..
06/22 R&D COSTS GROWING, ROCHE SHINES AND : Its the EP report
06/21 NOVO NORDISK A/S : receives positive 17-2 vote from FDA Advisory Committee that ..
06/20 NOVO NORDISK A/S : receives positive 17-2 vote from FDA Advisory Committee that ..
06/19 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
06/19 NOVO NORDISK A/S : - Share repurchase programme
06/17 NOVO NORDISK A/S : files to add Lantus-matching CV data to Tresiba`s European la..
06/16 NOVO NORDISK A/S : FDA posts briefing materials prior to Advisory Committee meet..
06/16 NOVO NORDISK A/S : FDA posts briefing materials prior to Advisory Committee meet..
06/15 NOVO NORDISK A/S : to present 60 abstracts at 77th Annual American Diabetes Asso..
06/15 NOVO NORDISK A/S : Patent Issued for Dose Setting Mechanism for an Injection Dev..
06/15 NOVO NORDISK A/S : Study Findings from Novo Nordisk Provide New Insights into Pr..
06/15 NOVO NORDISK A/S : Patent Issued for Methods for Producing Peptides Using Engine..
06/15 SUNUNU : Open for Business
06/14 NOVO NORDISK A/S : submits application in the EU for including data from the DEV..
06/13 NOVO NORDISK A/S : - Share repurchase programme
06/13 NOVO NORDISK A/S : New LEADER analysis shows Victoza® reduces cardiovascular ris..
06/12 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
06/12 NOVO NORDISK A/S : Switching to Tresiba® provides significant reductions in bloo..
06/09 NOVO NORDISK A/S : FDA Approves New Novo Nordisk Treatment for Patients with Hem..
06/09 NOVO NORDISK A/S : New Findings from Novo Nordisk in the Area of Proinsulin Repo..
06/09 NOVO NORDISK A/S : Research Conducted at Novo Nordisk Has Updated Our Knowledge ..
06/07 NOVO NORDISK A/S : Refixia (nonacog beta pegol; N9-GP) approved
06/07 INNATE PHARMA : French Biotech Strikes Deal with Novo Nordisk for New Cancer Dru..
06/06 NOVO NORDISK A/S : Refixia® (nonacog beta pegol; N9-GP) approved
06/06 NOVO NORDISK A/S : - Share repurchase programme
06/06 INNATE PHARMA : and Novo Nordisk pen early I-O cancer drug deal
06/05 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
06/05 INNATE PHARMA : strengthens its proprietary pipeline with the acquisition of ant..
06/03 INNATE PHARMA : acquires anti-C5aR, a first-in-class clinical-stage antibody, fr..
06/01 Diabetes Injection Pen Market 2017 - Novo Nordisk, Sanofi S.A., Eli Lilly and..
06/01 NOVO NORDISK A/S : Researchers Submit Patent Application, "Insulin-Containing Pr..
06/01 NOVO NORDISK A/S : receives US FDA approval of REBINYN (nonacog beta pegol; N9-G..
06/01 BIOTECH MOVERS : Novo Nordisk A/S (ADR) (NYSE:NVO) and EXACT Sciences Corporatio..
05/31 ABBVIE : Novo Nordisk and Takeda Have the Best Reputations Among Pharma Companie..
05/31 NOVO NORDISK A/S : receives US FDA approval of REBINYN® (nonacog beta pegol; N9-..
05/31 SANOFI : Novo hopes hypoglycaemia data will boost Tresiba
05/30 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
05/29 THE BUSINESS RESEARCH COMPANY : Americas accounted for $11.1 billion in diabetes..
05/29 THE BUSINESS RESEARCH COMPANY : Asia accounted for $2.8 billion in the diabetes ..
05/29 NOVO NORDISK A/S : submits application in the US for including data from the DEV..
05/27 NOVO NORDISK A/S : submits application in the US for including data from the DEV..
05/27 NOVO NORDISK A/S : submits application in the US for including data from the DEV..
05/26 ASTRAZENECA PLC (ADR)(NYSE : AZN)’s Bydureon Failed To Reach Statistical S..
05/25 NOVO NORDISK A/S : Reports on Clinical Trials and Studies from Novo Nordisk Prov..
05/25 NOVO NORDISK A/S : highlights partnership with Qatar`s Action on Diabetes
05/24 EXPRESS SCRIPTS : Insulin cost speeds away and diabetic Hoosiers are forced to m..
05/24 NOVO NORDISK A/S : - Share repurchase programme
05/24 NOVO NORDISK A/S : highlights partnership with Qatar's Action on Diabetes
05/24 NOVO NORDISK A/S : Sams and Dahl Strengthen Leadership Team With Appointment to ..
05/22 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
05/22 NOVO NORDISK A/S : Boost as drugs supplier gets Sh12m cold room
05/22 NOVO NORDISK A/S : Mission for Essential Drugs sets up Sh12m cold room for diabe..
05/17 NOVO NORDISK A/S : When diabetes and pro cycling meet
05/17 NOVO NORDISK A/S : Early response to Saxenda® resulted in weight maintenance and..
05/16 NOVO NORDISK A/S : DONG Energy - Historical partnership saves the climate from 2..
05/16 NOVO NORDISK A/S : Novelion CEO quits Novo Nordisk board due to NASH conflict
05/16 NOVO NORDISK A/S : Change in composition of the Board of Directors of Novo Nordi..
05/15 NOVO NORDISK A/S : - Share repurchase programme
05/11 NOVO NORDISK A/S : Launches Xultophy® 100/3.6 insulin degludec and liraglutide i..
05/11 NOVO NORDISK A/S : Clayton swaps YMCA land near Novo Nordisk
05/11 NOVO NORDISK A/S : Endocrine Society Lauds Novo Nordisk for Commitment to Afford..
1  2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ( DKK)
Sales 2017 115 848 M
EBIT 2017 50 067 M
Net income 2017 38 091 M
Finance 2017 18 034 M
Yield 2017 2,68%
P/E ratio 2017 18,71
P/E ratio 2018 16,96
EV / Sales 2017 4,72x
EV / Sales 2018 4,51x
Capitalization 565 022 M
More Financials
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 285  DKK
Spread / Average Target -1,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S15.55%86 251
JOHNSON & JOHNSON18.34%363 694
ROCHE HOLDING LTD.8.21%224 549
NOVARTIS12.55%222 848
PFIZER3.97%201 105
MERCK AND COMPANY11.33%179 263
More Results